Skip to Main Content
Muzumdar Lab
YSM Home

INFORMATION FOR

Sherry Agabiti, PhD

Associate Research Scientist in Genetics
DownloadHi-Res Photo

About

Titles

Associate Research Scientist in Genetics

Biography

Sherry is an associate research scientist studying the impact of p53 mutants on tumor evolution. She received her undergraduate degree from the University of Connecticut in Physiology & Neurobiology and English and then completed her Ph.D. at the University of Connecticut in Pharmaceutical Sciences. Her long-term research interests include understanding tumor evolve to avoid apoptosis and identifying thera vulnerabilities in pancreatic and lung cancers. Outside the lab, she enjoys gardening, following Formula 1, and curling up with a cup of tea and a whodunnit.

Last Updated on February 26, 2026.

Appointments

  • Genetics

    Associate Research Scientist
    Primary
    Genetics

Other Departments & Organizations

Education & Training

PhD
University of Connecticut, Pharmaceutical Sciences
BS
University of Connecticut, Physiology/ Neurobiology, English

Research

Research at a Glance

Yale Co-Authors

Frequent collaborators of Sherry Agabiti's published research.

Publications

2026

  • Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas.
    Ruiz CF, Ge X, McDonnell R, Agabiti SS, McQuaid DC, Tang A, Kharwa M, Goodell J, Saavedra-Pena RDM, Wing A, Li G, Medici NP, Robert ME, Varshney RR, Rudolph MC, Gorelick FS, Wysolmerski J, Canals D, Haley JD, Rodeheffer MS, Muzumdar MD. Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. Cancer Discov 2026 PMID: 42053430, DOI: 10.1158/2159-8290.CD-25-0734.
    Peer-Reviewed Original Research
    This study investigates how dietary fat composition influences pancreatic cancer, showing that monounsaturated fats promote tumor growth while polyunsaturated fats reduce risk by enhancing ferroptosis sensitivity.
    Full Summary
  • Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development
    Garcia CC, Venkat A, McQuaid DC, Agabiti SS, Tong A, Mathew B, Cardone RL, Starble R, Ruiz CF, Zheng C, Sogunro A, Jacox JB, Loh KH, Kibbey RG, Krishnaswamy S, Muzumdar MD. Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development. Nature Communications 2026 DOI: 10.1038/s41467-026-69821-2.
    Peer-Reviewed Original Research
    This study investigates how beta cell-derived cholecystokinin drives obesity-associated pancreatic cancer development, showing that targeting endocrine signaling could prevent tumor progression in obesity-related contexts.
    Full Summary

Academic Achievements & Community Involvement

Patents

Get In Touch

Contacts

Email